meta
|
Preg
- medecines during pregnancy KB
Search
Teriflunomide
Overall results
Study description
Excluded studies
Table
Graphic
auto
during pregnancy (anytime or not specified)
1st trimester
2nd trimester
3rd trimester
2nd and/or 3rd trimester
throughout pregnancy
early pregnancy
days before delivery
late pregnancy
preconception-only
periconceptional
preconceptional for kinetic reason
at least 1st trimester
3 months (or more) before pregnancy or during pregnancy
1st and 2nd trimester
3 months or more before pregnancy or1st trimester
Whatever the period exposition
individual studies
Outcome
TE
95% CI
n cases
n exposed
k
Pub. bias
Growth parameters and prematurity
Low birth weight (< 2500g)
Barataud-Reilhac A (Control unexposed, sick), 2019
1
1.66
[
0.49
; 5.70]
98
23
not evaluable
Preterm (< 37 weeks)
Barataud-Reilhac A (Control unexposed, sick), 2019
1
0.25
[
0.01
; 4.12]
94
23
not evaluable
Maternal consequences
Caesarean
Barataud-Reilhac A (Control unexposed, sick), 2019
1
1.01
[
0.37
; 2.74]
255
23
not evaluable
Neonatal disorders
Neonatal medical care
Barataud-Reilhac A (Control unexposed, sick), 2019
1
0.50
[
0.03
; 8.44]
48
23
not evaluable
Intrauterine deaths
Early intrauterine death (< 22 weeks)
Barataud-Reilhac A (Control unexposed, sick), 2019
1
0.82
[
0.20
; 3.44]
81
47
not evaluable
Elective/induced termination of pregnancy
Barataud-Reilhac A (Control unexposed, sick), 2019
1
4.97
[
2.75
; 8.99]
236
47
not evaluable
Late intrauterine deaths (> 22 weeks)
Barataud-Reilhac A (Control unexposed, sick), 2019
1
1.56
[
0.09
; 27.10]
10
47
not evaluable
Therapeutic terminations of pregnancy
Barataud-Reilhac A (Control unexposed, sick), 2019
1
1.57
[
0.21
; 11.93]
22
47
not evaluable
0.0
50.0
1.0
